Migraine prophylaxis-all just antibodies? Medical and nonmedical migraine preventive treatment in times of CGRP antibodies

被引:0
|
作者
Hamann, Till [1 ]
Kamm, Katharina [2 ]
Kropp, Peter [3 ]
Rimmele, Florian [1 ]
Juergens, Tim Patrick [1 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Kopfschmerzzentrum Nord Ost, Gehlsheimer Str 20, D-18147 Rostock, Germany
[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Neurol Klin & Poliklin, Oberbayr Kopfschmerzzentrum, Munich, Germany
[3] Univ Med Rostock, Inst Med Psychol & Med Soziol, Kopfschmerzzentrum Nord Ost, Rostock, Germany
来源
SCHMERZ | 2020年 / 34卷 / 06期
关键词
Receptors; calcitonin gene-related peptide; Immunotherapy; Analgesics; Prevention; Medication overuse; CORTICAL SPREADING DEPRESSION; PREVALENCE; TOPIRAMATE; HEADACHE; BURDEN;
D O I
10.1007/s00482-020-00500-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background Migraine is a frequently underdiagnosed disease that is associated with a high burden on affected patients. There are a variety of prophylactic treatment options available, that have been expanded with the introduction of the CGRP-(receptor-)antibodies. Objectives Status of pharmacologic and nonpharmacologic preventive treatment in migraine therapy. Methods Analysis and evaluation of internationally published articles concerning preventive treatment of episodic and chronic migraine. Results There are many approved medications for migraine prophylaxis with different evidence. The possibilities were further expanded with CGRP antibodies. Comparative studies of the new antibodies with previous prophylactic drugs have not yet been published, so it's unclear whether the antibodies are therapeutically superior. What should be emphasized is their rapid onset of action and their good tolerance. Basically, an individual choice of prophylaxis, which is based on affectedness, comorbidities and comedication, makes sense. In addition, a combination with nondrug measures is always mandatory. Conclusions A variety of medicinal and non-medicinal measures are available for the treatment of migraine, which should be used multimodally.
引用
收藏
页码:476 / 485
页数:10
相关论文
共 50 条
  • [41] Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
    de Meira Grava Simioni, Caio Vinicius
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2022, 80 (05) : 214 - 217
  • [42] CGRP Monoclonal Antibodies in the Treatment of Migraine in Elderly Patients: A Single Center Experience
    Patel, P.
    Lee, M.
    Shadbehr, N.
    Kriegler, J. S.
    Mays, M.
    Burstein, T.
    Ahmed, Z.
    HEADACHE, 2020, 60 : 8 - 8
  • [43] Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Migraine Preventative Treatment
    Salim, Amira
    Najjar, Atia
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [44] Efficacy and Safety of Anti- CGRP Monoclonal Antibodies for Migraine Preventative Treatment
    Salim, A.
    Najjar, A.
    Ahmed, Z.
    Mata, I
    HEADACHE, 2023, 63 : 131 - 131
  • [45] Safety concerns of treatment with anti-CGRP monoclonal antibodies in patients with migraine
    van der Arend, Britt W. H.
    van Veelen, Nancy
    de Ruijter, Joelle E. T.
    Olsen, Michael H.
    van den Brink, Antoinette Maassen
    Terwindt, Gisela M.
    CEPHALALGIA, 2023, 43 (1supp) : 233 - 233
  • [46] It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
    Kubota, Gabriel Taricani
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2022, 80 (05) : 218 - 226
  • [47] Persist-spain: peristence of anti-CGRP monoclonal antibodies as migraine preventive treatment after one year
    Diaz Insa, Samuel
    Huerta, Mariano
    Belvis, Robert
    Rodriguez Vico, Jaime
    Nieves, Candela
    Munoz, Albert
    Morollon, Noemi
    Jaimes, Alex
    Olivier, Marina
    Campoy, Sergio
    Gomez Garcia, Andrea
    CEPHALALGIA, 2023, 43 (1supp) : 264 - 264
  • [48] Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
    Aditya, Suruchi
    Rattan, Aditya
    SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2023, 11 (01) : 11 - 18
  • [49] Anti-CGRP monoclonal antibodies in migraine: current perspectives
    Giamberardino, Maria Adele
    Affaitati, Giannapia
    Curto, Martina
    Negro, Andrea
    Costantini, Raffaele
    Martelletti, Paolo
    INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (08) : 1045 - 1057
  • [50] CGRP-targeted antibodies in difficult-to-treat migraine
    de Vries, Tessa
    MaassenVanDenBrink, Antoinette
    NATURE REVIEWS NEUROLOGY, 2019, 15 (12) : 688 - 689